LTX-315 treatment induces complete and specific regression of disseminated tumors in a novel mesenchymal three tumor model

KVALHEIM G.1, WANG MY.1, NESTVOLD J.2, CAMILIO CA.3, ROLSTAD B.2, SVEINBJØRNSSON B.3, AREFFARD A4 AND REKDAL Ø4
Oslo University Hospital – Norwegian Radium Hospital1, University of Oslo2, University of Tromsø3, Lytix Biopharma4

Background
LTX-315 is a membrane active host-defence peptide representing a novel oncolytic treatment principle applied as intralesional therapy.

Aim
To investigate whether LTX-315 induce abscopal effect in a novel rat mesenchymal three-tumor sarcoma model (rTMSC)

Figure 1. Chemical structure of LTX-315

Figure 2. Study design of the three-tumor model

Figure 3. LTX-315 eradicates treated and non-treated lesions in the three-tumor rTMSc model

Figure 4. LTX-315 induce long term protective immune responses

Conclusions
- Here we show for the first time that intralesional treatment of one single lesion with LTX-315 (Oncopore™) is sufficient to cure animals with disseminated tumors.
- Systemic and long lasting protective immune responses was obtained in LTX-315 cured animals.
- LTX-315 represents a novel intralesional therapeutic strategy with potential to induce clinical responses in metastatic diseases.
- A phase 1/2a study is in progress with LTX-315.

References
Camilio et al., Cancer Immunol Immunother, 2014.